A Wilmore woman made quite the discovery after receiving results from a DNA kit, one that would lead to a shocking diagnosis.

23andMe has been testing the waters for a buyer for Lemonaid Health, the virtual-care business it bought in 2021 for $400 million in cash and stock, people with knowledge of the efforts told BI.

At-home DNA testing is no longer in high demand — and critics have raised concerns about unreliable tests and privacy.

Genetic testing pioneer 23andMe is looking at strategic alternatives, including a possible sale, it said Tuesday, months ...

23andMe CEO Anne Wojcicki sounded optimistic ... Company's mission and believe deeply in the value of the personalized health and wellness offering that you have articulated, it is also clear ...

The testing company ended last year with $79 million and told investors it will need to raise money to fund its operations ...

Me (ME) forms special board committee to explore strategic alternatives, including sale, restructuring, or business ...

SUNNYVALE, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics company with a mission to help ...

23andMe Holding Co. has launched a new polygenic risk score (PRS) report for osteoporosis, available to 23andMe+ Premium members. This report assesses an individual's genetic likelihood of ...

The struggling health company bought the virtual-care startup Lemonaid in 2021 for $400 million. 23andMe's stock plummeted after a 2023 data breach exposed millions of customer accounts.